Fmr LLC Has $701,000 Stock Holdings in 2seventy bio, Inc. (NASDAQ:TSVT)

Fmr LLC lifted its stake in 2seventy bio, Inc. (NASDAQ:TSVT) by 22.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 148,545 shares of the company’s stock after purchasing an additional 26,738 shares during the quarter. Fmr LLC owned 0.29% of 2seventy bio worth $701,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of TSVT. Marshall Wace LLP increased its position in shares of 2seventy bio by 50.4% in the second quarter. Marshall Wace LLP now owns 667,023 shares of the company’s stock worth $2,568,000 after acquiring an additional 223,408 shares in the last quarter. Venator Management LLC lifted its holdings in shares of 2seventy bio by 49.2% in the second quarter. Venator Management LLC now owns 485,000 shares of the company’s stock valued at $1,867,000 after purchasing an additional 160,000 shares in the last quarter. Stonepine Capital Management LLC acquired a new stake in shares of 2seventy bio in the second quarter worth $385,000. Susquehanna Fundamental Investments LLC grew its holdings in shares of 2seventy bio by 39.1% during the second quarter. Susquehanna Fundamental Investments LLC now owns 192,319 shares of the company’s stock valued at $740,000 after buying an additional 54,076 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in 2seventy bio during the third quarter valued at $80,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

2seventy bio Price Performance

NASDAQ:TSVT opened at $3.21 on Wednesday. The stock has a market cap of $165.60 million, a PE ratio of -1.73 and a beta of 1.69. 2seventy bio, Inc. has a fifty-two week low of $2.89 and a fifty-two week high of $6.40. The stock’s 50-day moving average is $4.25 and its two-hundred day moving average is $4.35.

2seventy bio Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.